Nicotinamide Riboside Supplementation and Exercise Training to Promote Healthy Longevity

Last updated: July 8, 2025
Sponsor: Finis Terrae University
Overall Status: Active - Recruiting

Phase

N/A

Condition

Metabolic Disorders

Treatment

Nicotinamide Riboside (NR)

Placebo

Clinical Study ID

NCT06425042
23-041
  • Ages 60-80
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The prevalence of age-related chronic diseases (like obesity, type 2 diabetes and cardiovascular diseases) is mounting worldwide, reaching pandemic proportions. These age-related chronic diseases are associated with diminished skeletal muscle mitochondrial function in humans. Nicotinamide adenosine dinucleotide (NAD) is a coenzyme that regulates mitochondrial function, therefore, plays an important role in energy metabolism. Importantly, it has been shown that high cellular NAD+ levels as well as a high NAD+/NADH ratio promote metabolic and mitochondrial health. In contrast, NAD+ bioavailability declines upon aging in humans as well as in animal models of metabolic disorders and type 2 diabetes. These findings fuel the notion of boosting the NAD+ bioavailability in order to improve metabolic disturbances and mitochondrial dysfunction in aged individuals. Supplementation with nicotinamide riboside (NR), a naturally occurring form of vitamin B3, boosts cellular NAD+ levels. However, in contrast to animal studies, NR supplementation in humans has so far been unsuccessful in improving skeletal muscle mitochondrial function, exercise capacity or insulin sensitivity. Interestingly, Recently, it has been suggested that metabolic conditions where NAD+ levels become limited, is needed for NR supplementation to exert beneficial health effects. This metabolic condition could be achieved by exercise. However, studies combining NR and exercise are lacking, and that is why we will perform the present study.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Participants are able to provide signed and dated written informed consent prior toany study specific procedures

  • Aged ≥ 60 and ≤ 80 years

  • Body mass index (BMI) 25 - 35 kg/m2

  • Stable dietary habits (no weight loss or gain > 5 kg in the past 3 months)

  • No signs of active cardiovascular disease, liver or kidney malfunction

Exclusion

Exclusion Criteria:

  • Patients with congestive heart failure and and/or severe renal and or liverinsufficiency

  • Uncontrolled hypertension

  • Any contra-indication for MRI scanning

  • Alcohol consumption of > 3 servings per day for man and >2 servings per day forwoman

  • Smoking

  • Unstable body weight (weight gain or loss > 5kg in the last 3 months)

  • Engagement in structured exercise activities > 2 hours a week

  • Previous enrolment in a clinical study with an investigational product during thelast 3 months or as judged by the Investigator which would possibly hamper our studyresults

  • Use of food supplements containing NR or Resveratrol (similar working mechanisms)

Study Design

Total Participants: 28
Treatment Group(s): 2
Primary Treatment: Nicotinamide Riboside (NR)
Phase:
Study Start date:
March 01, 2024
Estimated Completion Date:
March 31, 2026

Connect with a study center

  • Finis Terrae University

    Santiago, Region Metropolitana
    Chile

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.